Cardiology Round-Up: Rivaroxaban Versus Warfarin in Obese Subjects; and More

Rivaroxaban or Warfarin for Venous Thromboembolism Management in Obese Patients

In a recent study, Paige Weaver, from the Department of Pharmacy at the Ascension Genesys Hospital in Grand Blanc, Michigan, USA, and collaborating researchers assessed rivaroxaban or warfarin for management of venous thromboembolism (VTE) in morbidly obese patients—a population they felt had a dearth of available data.

Sortilin to Omentin-1 Ratio in Peripheral Artery Disease

According to Silvia Giovannini and colleagues from the Università Cattolica del Sacro Cuore in Rome, Italy, recent research has correlated sortilin and omentin-1 in the blood with the severity of peripheral artery disease (PAD). The investigators conducted a study to evaluate the feasibility of the sortilitn:omentin-1 ratio as an “easy-to-measure marker in peripheral artery disease (PAD) in type-2 diabetic patients.”

Can AI Predict Cardiac Arrest Better Than a Doctor Can?

A new artificial intelligence approach can predict if and when heart patients might die of sudden cardiac arrest far more accurately than a doctor can, and could improve survival rates, according to its developers.

FDA Approves Mavcamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

The United States Food and Drug Administration (FDA) approved Mavacamten to treat patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) with class NYHA class II or III heart failure symptoms on April 28, 2022.¹ The timing of the announcement coincidentally coincided with a well attended online Twitter journal club hosted by CardioNerds that featured the EXPLORER-HCM and VALOR-HCM trials, which assessed the role of Mavacamten in oHCM patients.

Browse More Recent Selections in Cardiology Research